BAMF
APLS

BI Asset Management Fondsmaeglerselskab’s Apellis Pharmaceuticals APLS Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,510
Closed -$89K – 641
2024
Q1 		$89K Buy
+1,510
New +$96.3K ﹤0.01% 676

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's APLS Position: Q2 2024 in Review

BI Asset Management Fondsmaeglerselskab sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 1,510 shares — an estimated $89K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in APLS in Q1 2024 and held it in 1 quarter. The position peaked at $89K in Q1 2024. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 1,510 Apellis Pharmaceuticals shares in Q2 2024, an estimated $89K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Apellis Pharmaceuticals position peaked at $89K in Q1 2024.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2024, filed 14 Aug 2024.